819 results
Page 2 of 41
6-K
EX-99.2
zmcjul5c
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
f3d85w5qcg 64wlpl1v
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
z7dqu
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
EX-99.1
hto48nso231b15
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
EX-99.1
40mkf hkedn
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.3
n3ikt
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.5
hc1wm3rhf vsird0
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.4
tygew fqej
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
5e6k57 kxmaajj
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
lezkz443
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
afnspfgy
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
mwot9md
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.1
cmar1hlc6m49rgjajb
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.2
xepz2nf3b61r5x h8lyw
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
m283opf2jd
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
f6o2 9f23ebp95o4l3p6
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.3
ia5g8e1j
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.2
tcgz4
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
s992w69
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.2
duocdqu5y2 c67ii
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am